It has been recently revealed that the expression level of Oct4 is associated with unfavorable clinical prognosis and therapeutic responses in N-Myc-amplified neuroblastomas, but not in N-Myc-non-amplified tumors [86]. Here, POU5F1 is linked to neuroblastoma.